- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04063098
Glucose-homeostasis After Endoscopic Sleeve Gastroplasty
Effects of Endoscopic Sleeve Gastroplasty on Hormonal Markers of Glucose-homeostasis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Endoscopic sleeve gastroplasty (ESG) is a transoral endoscopic procedure that utilizes full-thickness sutures extending from the prepyloric antrum to the gastroesophageal junction, creating a tubular sleeve along the lesser curvature with a gastric volume of approximately 30%. After the first feasibility study was available in 2013, multiple investigators published data on safety and efficacy of ESG. A recent meta analysis of novel endoscopic procedures revealed four observational studies on ESG. At 6, 12 and 24 months pooled excessive weight loss (EWL) was 52%, 53%, and 60% while pooled total body weight loss (TBWL) was 16%, 17%, and 20%, respectively.
Aside from its efficacy in terms of body weight loss, only a small number of investigations addressed metabolic changes in response to ESG so far. In a large retrospective analysis, which observed the outcomes of 1000 patients following ESG, 13 of 17 cases of type 2 diabetes mellitus (T2DM), all 28 cases of hypertension, and 18 of 32 cases of dyslipidemia were in complete remission by the third month of follow-up.
Summarizing the available literature, knowledge about effects of ESG on metabolism and glucose homeostasis is scarce. Available studies are subject to significant limitations in terms of sample size and or generalizability of results. The present study aims at a comprehensive determination of changes in hormonal regulators of glucose homeostasis after ESG in comparison to the preoperative state. Up to date, there are no structured and detailed analyses available that investigate glucose homeostasis following ESG. Proper glucose homeostasis yields a significant impact on a patients' quality of life and may - if deteriorated - be accompanied by a plethora of somatic and psychological constraints. The results of the present study seeks to investigate glucose homeostasis following ESG in detail. This may help to identify patients in need for further assistance regarding their post-interventional lifestyle in order to avoid e.g. hypoglycemia, and to further characterize patients' cohorts that will likely benefit from ESG.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Markus Laimer, Prof. MD
- Phone Number: +41316323062 +41316323062
- Email: Markus.Laimer@insel.ch
Study Contact Backup
- Name: Andreas Melmer, MD
- Phone Number: +41316323062 +41316323062
- Email: Andreas.Melmer@insel.ch
Study Locations
-
-
-
Bern, Switzerland, 3010
- Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Planned ESG
- Written informed consent
- Male or female sex
- Age 18-65 years
- BMI ≥ 40 kg/m2 OR
- BMI ≥ 35 kg/m2 and obesity-related comorbidities except type 2 diabetes
Exclusion Criteria:
- Type 1 or Type 2 Diabetes
- Type 2 Diabetes according to pathological OGTT at visit 2
- Mandatory use of medical drugs that influence glucose metabolism
- Participant had bariatric procedures other than ESG
- Abdominal surgery influencing glucose metabolism
- Moderate to severe chronic kidney, liver, or pancreatic disease
- Pregnancy or breastfeeding
- Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: All participants
Participants scheduled for endoscopic sleeve gastroplasty
|
Oral glucose tolerance test (OGTT) after a 72-hours standardized diet.
OGTT will be performed 1 month prior to as well as 1, 3, 6, and 12 months after endoscopic sleeve gastroplasty
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the curve for plasma glucose in oral glucose tolerance test
Time Frame: From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Plasma glucose will be measured in oral glucose tolerance test following dapagliflozin and will be compared with concentrations measured following placebo.
Active and inactivated glucagon like peptide I will be measured.
|
From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the curve for glucagon-like peptide I in oral glucose tolerance test
Time Frame: From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Glucagon-like peptide I will be measured in oral glucose tolerance test following dapagliflozin and will be compared with concentrations measured following placebo.
Active and inactivated glucagon like peptide I will be measured.
|
From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Area under the curve for gastric inhibitory peptide in oral glucose tolerance test
Time Frame: From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Gastric inhibitory peptide will be measured in oral glucose tolerance test following dapagliflozin and will be compared with concentrations measured following placebo.
Active and inactivated glucagon like peptide I will be measured.
|
From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Area under the curve for glucagon in oral glucose tolerance test
Time Frame: From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Glucagon will be measured in oral glucose tolerance test
|
From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Area under the curve for somatostatin in oral glucose tolerance test
Time Frame: From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Somatostatin will be measured in oral glucose tolerance test
|
From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Area under the curve for non-acyl ghrelin in oral glucose tolerance test
Time Frame: From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Non-acyl Ghrelin will be measured in oral glucose tolerance test
|
From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Area under the curve for insulin in oral glucose tolerance test
Time Frame: From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Insulin will be measured in oral glucose tolerance test
|
From time-point 0 to 120 minutes during oral glucose tolerance test, measurement every 15 minutes
|
Collaborators and Investigators
Investigators
- Principal Investigator: Markus Laimer, Prof. MD, Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism, University Clinics Bern, Inselspital, Bern, Switzerland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ESG_01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity, Morbid
-
ClinTrio Ltd.UnknownMorbid Obesity Requiring Bariatric SurgeryBelgium, Germany, Portugal, Austria, Netherlands, Poland, Saudi Arabia
-
Centre Hospitalier Universitaire de NiceCompletedMorbid Obesity D009765France
-
Shanghai Jiao Tong University School of MedicineUnknown
-
Hospices Civils de LyonCentre de Recherche en Nutrition Humaine Rhone-Alpe; Institut National de Recherche... and other collaboratorsRecruiting
-
Endolumik, IncWest Virginia UniversityNot yet recruitingMorbid ObesityUnited States
-
Rijnstate HospitalRecruiting
-
Laval UniversityCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie...Recruiting
-
University of WashingtonUnited States Department of DefenseWithdrawn
-
Helsinki University Central HospitalActive, not recruiting
-
IHU StrasbourgWithdrawnMorbid Obesity
Clinical Trials on Oral glucose tolerance test
-
University Hospital Schleswig-HolsteinUniversity of KielRecruitingParkinson Disease | Nutritional and Metabolic Diseases | Sugar IntakeGermany
-
University College DublinCompletedHealthy SubjectsIreland
-
NYU Langone HealthCompletedGlucose Metabolism Disorders | Diabetes Mellitus | Prediabetic State | Diabetes, GestationalUnited States
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Children's Hospital of PhiladelphiaCystic Fibrosis FoundationRecruitingCystic Fibrosis | Cystic Fibrosis-related DiabetesUnited States
-
Ankara City Hospital BilkentRecruitingGestational Diabetes | Glucose Intolerance During PregnancyTurkey
-
Christophe De BlockUnknownDiabetes Mellitus | Stress HyperglycemiaBelgium
-
Zhujiang HospitalRecruitingDiabetes Mellitus | Prediabetes | Gestational Diabetes Mellitus | ProteomicsChina
-
University of NottinghamCompletedGastrointestinal DysfunctionUnited Kingdom
-
Seoul National University HospitalCompletedDiabete Mellitus | Pancreatectomy; Hyperglycemia